What is the recommended dosing and administration of swallowed fluticasone propionate for eosinophilic esophagitis?

Swallowed Fluticasone for Eosinophilic Esophagitis

For adults with EoE, use swallowed fluticasone propionate 880 mcg (4 puffs of 220 mcg/puff) twice daily for induction, and for children use age-based dosing: 440 mcg twice daily (2 puffs of 110 mcg/puff for ages 5-11) or 880 mcg twice daily (2 puffs of 220 mcg/puff for ages ≥12). 1, 2

Dosing Regimen

Adults (≥12 years)

• Induction therapy: 880 mcg twice daily (4 puffs of 220 mcg/puff) for 8-12 weeks 2
• Maintenance therapy: After achieving remission, can reduce to 440 mcg twice daily (2 puffs) 1
• Duration: Up to 6 months before reassessment 3

Children

• Ages 5-11 years: 440 mcg twice daily (2 puffs of 110 mcg/puff) 1, 3
• Ages <5 years: 176 mcg twice daily (2 puffs of 44 mcg/puff) 3
• Duration: Maximum 2 months per year before checking with physician due to growth concerns 3

Administration Technique

The proper swallowing technique is critical for efficacy:

1. Do NOT inhale - this is not for asthma treatment
2. Actuate the metered-dose inhaler directly into the mouth
3. Swallow immediately without inhaling
4. Do not eat or drink for 30 minutes after administration 2
5. Administer after meals to maximize esophageal contact time

Expected Outcomes

Histologic remission (the primary therapeutic goal):

• 50-65% achieve complete remission (<15 eos/hpf) at 3 months 1, 4
• 75% achieve remission with higher doses (1760 mcg daily) 5
• Response is better in younger, non-allergic patients 4

Symptom improvement:

• 57-67% achieve symptomatic relief 1
• Vomiting resolves in 67% of responders 4
• Dysphagia improves significantly 6

Endoscopic improvement:

• Furrows and exudates significantly decrease 6
• Reduces stricture development over time 2

Dose Reduction Strategy

After achieving remission at 3 months with 880 mcg twice daily:

• Reduce to 440 mcg twice daily 1
• 73% maintain remission at reduced dose 5
• If symptoms recur, return to higher dose 1

Predictors of Response

More likely to respond:

• Higher baseline eosinophil counts (median 76 vs 44 eos/hpf) 7
• Presence of eosinophilic microabscesses 7
• Younger age 4
• Non-allergic phenotype 4

Resistance patterns:

• Approximately 35% fail to achieve remission 1
• Extending therapy beyond 3 months in non-responders does not induce remission 5
• Consider alternative therapy (budesonide formulations, dietary elimination, or biologics) if no response by 3 months 2

Safety Considerations

Common side effects:

• Esophageal candidiasis (asymptomatic, resolves with antifungals) 3
• Oral thrush (less common with proper swallowing technique)

Monitoring requirements:

• Children: Monitor growth parameters; growth suppression possible with long-term use 1, 3
• All patients: No routine adrenal function testing needed for short-term use, but consider if using >6 months 1
• Reassess histology at 8-12 weeks to confirm response 2

Critical Pitfalls to Avoid

1. Do not use inhaled technique - patients must swallow, not inhale, or the medication will not reach the esophagus
2. Do not stop after symptom improvement alone - histologic remission is the goal; symptoms may improve without adequate eosinophil reduction 1
3. Do not continue beyond 3 months if no response - switch to alternative therapy rather than extending ineffective treatment 5
4. Do not use in children >2 months/year without physician reassessment due to growth concerns 3

Comparison to Other Formulations

While fluticasone remains widely used due to cost and accessibility 8, 9, budesonide orodispersible tablets demonstrate superior efficacy (84% clinico-histologic remission vs 62% for fluticasone) and are now the preferred topical steroid where available 2, 10. However, fluticasone remains an effective and appropriate first-line option, particularly when cost or insurance coverage is a barrier 8, 9.

Long-term Maintenance

Relapse rates are high (45-87%) after discontinuation 1, 3, therefore:

• Continue maintenance therapy indefinitely in responders 2
• Use lowest effective dose for maintenance 1
• Long-term use (up to 68 months) demonstrates sustained efficacy without serious adverse effects in children 3